Summary
- A disease affecting more than 750M – with 80% patients dissatisfied.
- Current treatments are unable to follow healthy thyroid gland release cycles.
- ProLevi develops a modified release thyroid hormone formulation mimicking the circadian rhythm.
Hypothyroidism
Thyroid hormone — Control development & metabolism
Thyroid hormone — Control development & metabolism
Hypothyroidism affects 10% of the global population. 70-80% patients are dissatisfied with current treatment (Hegedus L, Nat Rev Endo,2022). For 15-20% of all patients, T4 is ineffective because of underlying genetics or unidentified mechanisms.
T3, the active hormone controls cell metabolism, heart rate, body temperature, peristalsis, muscle contractions and apoptosis. Symptoms of hypothyroidism include fatigue, weight gain, cognitive decline, increase in cholesterol levels, dry skin and hair loss.
Prolevi deploys hormonal formulations that synchronizes with natural circadian rhythm for personalized patient treatment. We improve long term side effects, overdosing and patient compliance with our platform patent- pending drug formulations.
80% of patients are dissatisfied
with current treatment*
28% treated with antidepressants (Sweden- SE)**
1 in 10 too ill to work- 600M €/yr loss (SE)**
millions affected
dissatisfied*
millions report poor life quality
millions administered clinically ineffective treatment (non-responders)
Thyroid hormone levels follow the circadian rhythm
T3 and TSH levels follow the circadian clock
Problem with current treatments
- Failure to mimic T3 natural release cycles
- T3 today is immediate release with short half life
- Poor patient compliance (T3 dosing thrice a day)
- Overdosing and long-term side-effects
Our solution
A modified release thyroid hormone formulation mimicking the circadian rhythm
Intellectual Property
Our Team
Sahil Gupta, CEO,
Founder
Daniel Bar-Shalom, Head of Formulation, Founder
Birte Nygaard,
Medical Advisor
Giulia Brigante,
Scientific Advisor
Wilmar M. Wiersinga, Scientific Advisor
Kush Punyani,
Co-Founding Investor
Board Member
Edvard Hall,
Co-Founding Investor
Board Member, Chair
Anna Gisselsson,
Board Member,
Investor
Johan Källstrand,
Co-Founding Investor
Stefan Kilian Investor/Advisor
Klaus Dugi
Investor/Advisor
Hanns-Georg Klein
Lars Moberg,
Chief Financial Officer
Company vision
Prolevi’s long term vision is to treat metabolic disorders deploying our platform patent pending technology. We personalize the formulations in synergy with circadian rhythm.
Prolevi will initially focus on bringing treatment to hypothyroid patients. 80% of patients, largely women remain dissatisfied and ignored with the current treatment. They suffer from broad symptoms despite normal hormone blood levels with existing therapy. This is due to lack of reliable tests, non-effective treatment, and unstandardized worldwide screening (that should include fT3, fT4, rT3, T3, T4, and TSH). Prolevi’s solution ensures personalized therapy based on patient’s baseline characteristics.
Contact us
Medicon Village,
Scheelevägen 2, 223 81 Lund Sweden
Phone: +49 15205359402